Open AccessThis article is
- freely available
EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
Department of Biopathology, Centre Hospitalier Universitaire de Montpellier, Montpellier 34000, France
Faculté de Médecine de Montpellier, Université de Montpellier I, Montpellier 34000, France
Department of Surgery, Centre Hospitalier Universitaire de Montpellier, Montpellier 34000, France
Department of Biostatistic, CRLC Val d'Aurelle, Montpellier 34000, France
* Author to whom correspondence should be addressed.
Received: 7 February 2013; in revised form: 20 February 2013 / Accepted: 25 February 2013 / Published: 4 March 2013
Abstract: Accumulation of molecular alterations, including EGFR overexpression and mutations in KRAS and BRAF, contribute to colorectal carcinogenesis. Since intestinal-type adenocarcinoma (ITAC) of the nasal cavity and paranasal sinus has morphologic and phenotypic features that are usually indistinguishable from colorectal cancer (CRC), it is likely that both tumor types share equivalent genetic alterations. Data from a series of 43 patients treated surgically for ITAC in Montpellier, France between November 1998 and December 2012 were collected. Tumors were characterized for mutations in KRAS and BRAF as well as EGFR overexpression. Kaplan-Meier survival curves were constructed using overall survival as the primary end points. Patient survival was analyzed using the hazards ratio. Twenty seven tumors (63%) showed EGFR positivity and 30% exhibited a high expression level (+2/+3). KRAS mutations were detected in 43% of cases. BRAF mutations were identified in 3.6% of specimens. Patients with age superior to 60 years, metastatic status, and KRAS mutations had significant overall survival values (p = 0.026, p = 0.001 and p = 0.03, respectively). Our results indicate that KRAS mutations and EGFR expression are frequent in ITAC and that KRAS mutations predict good patient prognosis in ITAC. Finally, EGFR directed molecular treatments could be investigated in a subset of patients affected by ITAC.
Keywords: ITAC; KRAS; BRAF; EGFR expression; prognosis marker
Citations to this Article
Cite This Article
MDPI and ACS Style
Szablewski, V.; Solassol, J.; Poizat, F.; Larrieux, M.; Crampette, L.; Mange, A.; Bascoul-Mollevi, C.; Costes, V. EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. Int. J. Mol. Sci. 2013, 14, 5170-5181.
Szablewski V, Solassol J, Poizat F, Larrieux M, Crampette L, Mange A, Bascoul-Mollevi C, Costes V. EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. International Journal of Molecular Sciences. 2013; 14(3):5170-5181.
Szablewski, Vanessa; Solassol, Jérôme; Poizat, Flora; Larrieux, Marion; Crampette, Louis; Mange, Alain; Bascoul-Mollevi, Caroline; Costes, Valérie. 2013. "EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma." Int. J. Mol. Sci. 14, no. 3: 5170-5181.